ArticleThoracic cancer2018

Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer.

Puyuan Xing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.